Clinical Trial

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel
Protocol Amendment History 31 amendments
This ClinicalTrials.gov record has been amended 31 times since 2024-05-30; most recent amendment 2026-03-26.
Trial Details
NCT Number NCT06445062
Lead Sponsor Revolution Medicines, Inc.
Conditions Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment 1,130 participants
Start Date 2024-05-24
Primary Completion 2027-05-15 (estimated)
Study Completion 2027-07-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-29